WEB Clinical Assessment of IntraSaccular Aneurysm Therapy (WEBCAST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01778322 |
Recruitment Status :
Completed
First Posted : January 29, 2013
Last Update Posted : March 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Intracranial Aneurysm | Procedure: Intracranial aneurysm embolization |
The following parameters will be evaluated as part of this study:
- Aneurysm morphology
- Aneurysm size
- For ruptured aneurysms: Hunt and Hess Classification of Subarachnoid Hemorrhage (SAH)
- Size of the embolization device(s) used in the procedure
- Intra-procedural assessment of aneurysm occlusion and flow stasis
- Degree of aneurysm occlusion post-procedure (percentage occlusion, Raymond Scale and other scores as appropriate)
- Aneurysm occlusion durability
- Recanalization rate
- Device-related changes in Modified Rankin Scale from baseline
- Complications/adverse events
- Rebleed/new bleed
Study Type : | Observational |
Actual Enrollment : | 51 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | WEB Clinical Assessment of IntraSaccular Aneurysm Therapy |
Study Start Date : | December 2011 |
Actual Primary Completion Date : | December 2015 |
Actual Study Completion Date : | December 2019 |

Group/Cohort | Intervention/treatment |
---|---|
Index Embolization Cohort
WEB Aneurysm Embolization System
|
Procedure: Intracranial aneurysm embolization
Treatment of intracranial aneurysms |
- Durability of occlusion [ Time Frame: 6 months ]Evaluated by the Corelab
- Recurrence/recanalization rate [ Time Frame: 6 months ]Evaluated by the Corelab, based on Raymond Roy occlusion scale
- Modified Raymond Scale [ Time Frame: 6 months ]Evaluation of patient's functional level of activity by the physician
- Percentage occlusion of target aneurysm [ Time Frame: 6 months ]Evaluated by the Corelab
- Fluoroscopy time [ Time Frame: procedure ]Duration of fluoroscopy time will be recorded during the procedure

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Subjects with:
- Diameter and width of the aneurysm is appropriate size for treatment with the WEB Aneurysm Embolization System per device Instructions for Use
Inclusion Criteria:
- Must be at least 18 years of age
- Must sign and date an IRB/EC-approved written informed consent prior to initiation of any study procedures
Exclusion Criteria:
- Must not have clinical or angiographic evidence of vasospasm
- Must not have lesion with characteristics unsuitable for endovascular treatment
- Must not have neurologic or psychiatric conditions, which preclude ability to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule
- Must not be concurrently involved in another investigational or post-market study
- Must not have received any investigational device for treatment of the target intracranial aneurysm prior to entry into this trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01778322
Denmark | |
Rigshospitalet | |
Copenhagen, Denmark, 2100 | |
France | |
Hôpital Beaujon | |
Clichy, France, 92118 | |
CHU Gui de Chauliac | |
Montpellier, France, 34295 | |
CHU Reims Maison Blanche | |
Reims, France, 51092 | |
CHU Purpan | |
Toulouse, France, 31059 | |
CHU Bretonneau | |
Tours, France, 37000 | |
Germany | |
Uniklinik Koeln | |
Cologne, Germany, 50937 | |
Helios Klinikum | |
Erfurt, Germany, 99089 | |
Klinikum der Johann Wolfgang Goethe Universität | |
Frankfurt, Germany, 60528 | |
Klinikum Vest GmbH | |
Recklinghausen, Germany, 45657 | |
Klinikum Stuttgart- Katharinenhospital | |
Stuttgart, Germany, 70174 | |
Hungary | |
National Institute of Neurosciences | |
Budapest, Hungary, H-1145 |
Principal Investigator: | Laurent Pierot, MD | CHU Reims |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Microvention-Terumo, Inc. |
ClinicalTrials.gov Identifier: | NCT01778322 |
Other Study ID Numbers: |
CP 11-001 |
First Posted: | January 29, 2013 Key Record Dates |
Last Update Posted: | March 15, 2023 |
Last Verified: | August 2022 |
Intracranial Aneurysm Aneurysm Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases |
Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |